Navigation Links
AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Date:5/14/2008

turia), difficulty starting urination and/or weak urinary stream, and feeling that the bladder is not completely empty after urination. While current therapies provide some efficacy in BPH they are often associated with troublesome sexual side effects.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization.
News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental autho
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. AEterna Zentaris to Announce Third Quarter 2007 Financial and Operating Results on November 7, 2007
2. Amarin Announces Private Placement for up to $60 Million
3. NightHawk Radiology Holdings, Inc. Announces Dutch Tender Offer for Its Common Stock
4. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
5. Veria Announces Acquisition of Massage Envy Ltd.
6. TOFUTTI Announces First Quarter Results
7. Natural Alternatives International, Inc. Announces Third Quarter Results
8. eDiets.com(R) Announces Q1 2008 Results
9. Boston Scientific Announces FDA Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
10. United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results
11. The Blue Foundation for a Healthy Florida Announces $8 Million Initiative to Address Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2014)... 03, 2014 CS3 Technology, a Sage ... and support of Sage 100 ERP, Sage 500 ERP, ... America Million Dollar Club achiever for surpassing a million ... recognizes CS3 Technology and all Million Dollar Club achievers ... of Sage, its business partners and the mutual customers ...
(Date:9/3/2014)... (PRWEB) September 03, 2014 Health ... increases patient safety, decreases medical errors, and strengthens ... , To mark the important role health information ... IHS and others across the U.S. have joined ... Week , September 16-20, 2014. With the NHIT ...
(Date:9/3/2014)... Immersion Active (ImmersionActive.com ), the digital ... in the 2014 Content Marketing Awards presented by the ... leading awards program for people who create content for ... strategic purpose. , Immersion Active’s winning entry was ... Home Instead Senior Care®. This series addresses people who ...
(Date:9/3/2014)... (PRWEB) September 03, 2014 Independent ... use of appropriate evidence-based health care along the ... benefit from the expertise of accredited independent review ... health care system. , As a core function, ... often settle questions of medical necessity. Yet backed ...
(Date:9/3/2014)... (PRWEB) September 03, 2014 "What can you ... Thus begins "Margaret and Hillary," Book Eight in the ... Rhyse and published by Wyston Books, Inc . These ... wealthy friends in the richest town in America. , In ... as she helps to investigate a student’s murder plot. Her ...
Breaking Medicine News(10 mins):Health News:CS3 Technology Named a Sage Million Dollar Club Achiever for 2013-2014 2Health News:Innovative Healthcare Solutions (IHS) Celebrates National Health IT Week September, 15-19, 2014 2Health News:Immersion Active Wins Silver for Email Strategy in 2014 Content Marketing Awards 2Health News:Independent Review Expands Its Scope: Case Studies in Context 2Health News:Independent Review Expands Its Scope: Case Studies in Context 3Health News:Town Locked Down After Bombing and Murders in "Margaret and Hillary" - New Book Eight in the Margaret of Greenwich(R) Young Adult Series by R. L. Rhyse 2
... 1994, the team of Tchernev and Petrova from Alexandrovska ... cirrhosis caused by chronic Hepatitis C virus (HCV). They ... vascular lesions on the lower limbs, acute pain in ... labor-impairing fatigue. They were also intrigued by the presence ...
... for treatment of patients with chronic hepatitis B ... leads to the emergence of lamivudine-resistant hepatitis B ... with HBV. Sensitive methods for early detection of ... in treating patients with HBV infection. , To ...
... what you eat free of bacteria , , WEDNESDAY, Jan. 16 ... bear much of the burden for keeping the nation,s food ... at home. , Here are some common-sense precautions: , ... as eggs, are well-cooked before you eat them. Use a ...
... appears to be a distinctive sexual orientation and not ... "on their way" to lesbianism, according to new research ... study of 79 non-heterosexual women over 10 years found ... attraction to both sexes. In addition, the research appears ...
... Benefit All Babies, WHITE PLAINS, N.Y., Jan. 15 ... expectant moms --,initially overjoyed -- can be left feeling ... ever for moms to get the information they need., ... baby health,in the most convenient way possible," said Dr. ...
... American Academy of,Ophthalmology expresses its sadness at the ... inhibitors sparked major advances in the,treatment of eye ... angiogenesis, or blood vessel development., "Dr. Folkman,s ... all of,medicine," said H. Dunbar Hoskins, Jr., MD, ...
Cached Medicine News:Health News:Attention: Extra-hepatic manifestation of hepatitis C virus infection 2Health News:What is the more suitable for early detection of low abundant lamivudine-resistant mutants? 2Health News:Bisexuality not a transitional phase among women, according to new research 2Health News:March of Dimes Offers New Resources for Pregnancy and Baby Health 2Health News:March of Dimes Offers New Resources for Pregnancy and Baby Health 3Health News:American Academy of Ophthalmology Mourns Loss of Judah Folkman, MD, Pioneering Researcher 2
(Date:9/3/2014)... ,    ... ~   Kiadis Pharma B.V. ... biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, ... , MD PhD, as its Chief Medical Officer. ... at Ceronco Biosciences. Prior to that he was VP ...
(Date:9/2/2014)... 2014 Reportbuyer.com has added a new ... Technologies for Molecular Imaging Devices ... The objectives of this study are to ... used for diagnostic purposes, present global market measurements ... market segments as well as forecast market and ...
(Date:9/2/2014)... -- Numotion is pleased to announce the appointment of Mark ... Mark is a 30-year retired veteran of GE where ... and was a GE Company Officer since 1999 and a ... running business units within GE Healthcare, with the most recent ... "We are delighted to welcome Mark to our Board," ...
Breaking Medicine Technology:Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 2Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 3Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 4Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 5Global Markets and Technologies for Molecular Imaging Devices 2Global Markets and Technologies for Molecular Imaging Devices 3Global Markets and Technologies for Molecular Imaging Devices 4Global Markets and Technologies for Molecular Imaging Devices 5Global Markets and Technologies for Molecular Imaging Devices 6Global Markets and Technologies for Molecular Imaging Devices 7Global Markets and Technologies for Molecular Imaging Devices 8Global Markets and Technologies for Molecular Imaging Devices 9Global Markets and Technologies for Molecular Imaging Devices 10Global Markets and Technologies for Molecular Imaging Devices 11Global Markets and Technologies for Molecular Imaging Devices 12Global Markets and Technologies for Molecular Imaging Devices 13Global Markets and Technologies for Molecular Imaging Devices 14Global Markets and Technologies for Molecular Imaging Devices 15Global Markets and Technologies for Molecular Imaging Devices 16Global Markets and Technologies for Molecular Imaging Devices 17Global Markets and Technologies for Molecular Imaging Devices 18Global Markets and Technologies for Molecular Imaging Devices 19Global Markets and Technologies for Molecular Imaging Devices 20Global Markets and Technologies for Molecular Imaging Devices 21Global Markets and Technologies for Molecular Imaging Devices 22Global Markets and Technologies for Molecular Imaging Devices 23Global Markets and Technologies for Molecular Imaging Devices 24Global Markets and Technologies for Molecular Imaging Devices 25
... Tenn., Nov. 18, 2011 MedSolutions , ... services, today announced the launch of its Implantable ... evidence-based guidelines to ensure the clinical appropriateness of ... With the cost of each ICD/CRT-D ...
... Md., Nov. 18, 2011 The U.S. Food and ... ) to treat patients with acute lymphoblastic leukemia (ALL), ... coli derived asparaginase and pegaspargase chemotherapy drugs used ... ) Acute lymphoblastic leukemia is a ...
Cached Medicine Technology:MedSolutions Launches Implantable Cardiac Defibrillator Program to Reduce Unnecessary Surgeries 2MedSolutions Launches Implantable Cardiac Defibrillator Program to Reduce Unnecessary Surgeries 3FDA Approves Erwinaze to Treat a Form of Leukemia 2FDA Approves Erwinaze to Treat a Form of Leukemia 3
... Insulin-like growth factor II (IGF-II) is a ... the liver and is postulated to have mitogenic ... actions of IGF-II are mediated by binding to ... to the Type II IGF receptor, a monomeric ...
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
... proteohormone with a molecular weight of 16 kDa. ... and produced by adipocytes [1,2]. Leptin is thought ... body weight [1-3]. In the human, leptin levels ... women [4]. A relationship between serum leptin levels ...
... known as Anti-Mullerian Inhibiting Substance (AMH), is ... kDa monomers linked by disulfide bridges (1). ... (TGF-?) superfamily which includes TGF-? and the ... members of this superfamily are dimeric glycoproteins, ...
Medicine Products: